Amy Kruse is a PhD neuroscientist turned venture capital investor at Prime Movers Lab who previously ran neuroscience and human-performance programs for DARPA, giving her deep operational experience in translating brain science into real-world applications. She focuses specifically on neurotech investments that enhance human performance rather than just treat disease, and takes hands-on board roles helping founders navigate the scientific and regulatory complexity of brain-computer interfaces and advanced sensing technologies. Amy Kruse is a PhD neuroscientist turned venture capital investor at Prime Movers Lab who previously ran neuroscience and human-performance programs for DARPA, giving her deep operational experience in translating brain science into real-world applications. She focuses specifically on neurotech investments that enhance human performance rather than just treat disease, and takes hands-on board roles helping founders navigate the scientific and regulatory complexity of brain-computer interfaces and advanced sensing technologies.